Company Overview and News
KUALA LUMPUR (Aug 9): The FBM KLCI managed to hold its position above the 1,800-point level at mid-morning today, but gains were seen capped in line with the subdued regional markets.
HLFBF 7172 5198 1082 7412 7043 7077 2852 5029 5347 5225 1201 3301 TNABY 5819 2836 TNABF Q0F IHHHF 3719
KUALA LUMPUR (Aug 8): The FBM KLCI rose 0.39% at the midday break today, as gains in select index-linked blue chips lifted it closer to the 1,800-point mark, tracking the advance at regional markets.
5198 7113 5032 6432 TPGVF BATS 4162 7765 0096 7043 5168 5014 TGLVY 5029 5225 3301 MYPRY Q0F IHHHF HRGHY
KUALA LUMPUR (Aug 8): The FBM KLCI pared some of its gains at mid-morning today, struggling to breach the 1,800-point level.
PBLOF BATS 4162 7087 7043 1295 5168 5014 5007 KLKBY 5029 2445 2542 5225 3867 5517 7668 2739 MYPRY 2836 Q0F IHHHF HRGHY
KUALA LUMPUR (July 4): Based on the corporate announcements and news flow today, companies in focus on Thursday (July 5) may include: Serba Dinamik, Xian Leng, SCGM, Perdana Petroleum, TA Global, MNRB, China Automobile Parts and JMR.
4898 7108 6459 5229 7043 5158 BSMAF 7121 1818
KUALA LUMPUR (July 4): JMR Conglomeration Bhd has expanded its landbank in Seberang Perai Tengah, Penang through subscription of an additional 4.49 million new shares in its subsidiary TAG Steel Holdings Sdn Bhd (TSH) for RM4.49 million.
7043 BSMAF 1818
KUALA LUMPUR (June 18): The FBM KLCI is expected to resume trade on a cautious note today as the U.S.-China trade spat continues to weigh on global investor sentiment.
7293 5216 7043 0096
KUALA LUMPUR (June 14): Based on corporate announcements and news flow today, companies in focus on Monday (June 18) may include: Yinson Holdings Bhd, Datasonic Group Bhd, Sime Darby Plantation Bhd, Gamuda Bhd, Nexgram Holdings Bhd, JMR Conglomeration Bhd, and My EG Services Bhd.
7293 5216 7043 FXPL 0096
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...